IP Verse

Genzyme Corporation V. Novartis Gene Therapies, Inc. - 1:23-cv-00554

Explore the details of the Genzyme Corporation V. Novartis Gene Therapies, Inc. case under case number 1:23-cv-00554 involving a cause of action for Patent Infringement. Review key information about the parties involved, the patents in question, and the docket entries.

Case Details

Case Number
1:23-cv-00554
Filing Date
May 19, 2023
Cause of Action
Patent Infringement
Status
-
Nature of Suit
Patent

Parties Involved in the Case

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Novartis Gene Therapies, Inc. -
Genzyme Corporation -
Aventis Inc. -

Patents Involved in the Case

Patents not found - set an alert to get notified when patents are added.

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Nov 16, 2023NOTICE OF SERVICE of (1) Defendants' Responses and Objections to Plaintiffs' First Set of Interrogatories (Nos. 1-9), and (2) Defendants' Responses and Objections to Plaintiffs' First Set of Requests for Production of Documents and Things (Nos. 1-25) filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/16/2023)PACER Document
Nov 22, 2023NOTICE OF SERVICE of Defendants' Answering Claim Construction Brief and Exhibits filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/22/2023)PACER Document
Dec 6, 2023STIPULATION and [Proposed] Order Regarding the Exchange of Claim Construction Briefs by Aventis Inc., Genzyme Corporation. (Vavala, Donald) (Entered: 12/06/2023)PACER Document
Dec 6, 2023SO ORDERED, re 51 Stipulation and Proposed Order Regarding the Exchange of Claim Construction Briefs. Signed by Judge Richard G. Andrews on 12/6/2023. (nms)PACER Document
Dec 7, 2023NOTICE OF SERVICE of Plaintiffs Reply Claim Construction Brief filed by Aventis Inc., Genzyme Corporation.(Vavala, Donald) (Entered: 12/07/2023)PACER Document
Dec 15, 2023NOTICE OF SERVICE of Defendants' Sur-Reply Claim Construction Brief filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/15/2023)PACER Document
Dec 20, 2023Joint Motion Requesting Claim Construction Hearing - filed by Aventis Inc., Genzyme Corporation. (Vavala, Donald) Modified on 12/21/2023 (nms). (Entered: 12/20/2023)PACER Document
Dec 20, 2023APPENDIX re 54 Joint Claim Construction Brief, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibits 1-10)(Vavala, Donald) Modified on 12/21/2023 (nms). (Entered: 12/20/2023)PACER Document
Dec 20, 2023JOINT Claim Construction Brief, filed by Genzyme Corporation, Aventis Inc.. (Vavala, Donald) Modified on 12/21/2023 (nms). (Entered: 12/20/2023)PACER Document
Dec 21, 2023SO ORDERED Granting 56 Joint Motion Requesting Claim Construction Hearing. Signed by Judge Richard G. Andrews on 12/21/2023. (nms) (Entered: 12/21/2023)PACER Document
Jan 10, 2024Joint letter to Judge Andrews, from David E. Wilks, regarding Markman Hearing. (Wilks, David) Modified on 1/11/2024 (nms). (Entered: 01/10/2024)PACER Document
Jan 11, 2024ORAL ORDER: The request to continue the January 16, 2024, Markman (D.I. 58 ) is GRANTED. The parties are to file a joint status report due no later than 2/8/2024. Ordered by Judge Richard G. Andrews on 1/11/2024. (nms) (Entered: 01/11/2024)PACER Document